Leucovorin modulation of fluorouracil in advanced colorectal cancer;La modulation du 5-fluorouracile par l'acide folinique dans les cancers colorectaux avances

Revue de Medecine Interne

Volumn 18, Issue SUPPL. 4, 1997, Pages

  De Gramont, A ^a   Louvet, C ^a   Andre T ^b   Tournigand, C ^a   Raymond, E ^a   Molitor, J L ^a   Krulik, M ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔPITAL TENON   (France)

Author keywords

5FU; Leucovorin; Metastatic colorectal cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONFERENCE PAPER; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; NAUSEA; STOMATITIS; VOMITING;

EID: 0030756620     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(97)83768-X     Document Type: Conference Paper

References (26)

1. Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden PO. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal tumor adjuvant therapy group. Cancer 1994;73:556-62
2. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10:904-11
3. World Health Organization. WHO handbook for reporting results of cancer treatment. Genova, WHO, 1979
4. Guidelines for the reporting of adverse drug reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
5. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-81
6. Pinedo HM, Peters GFJ. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988;6:1653-64
7. Matsuoka H, Ueo H, Sugimachi K Akjyoshi T. Preliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor response. Cancer Invest 1992;10:265-9
8. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer. A tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997;15:368-81
9. Sobrero AF, Aschele C, Guglielmi AP et al. Synergisrn and lack of cross-resistance between short-term and continuous infusion to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Instit 1993;85:1937-44
10. Milano G, Étienne MC. Évolution de la pharmacocinétique à la pharmacogénétique. L'exemple du 5-fluorouracile. Rev Med Interne 1994;15:287-91
11. Machover D, Goldschmidt E, Chollet P et al. Treatment of advanced colorectal cancer and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986;4:685-96
12. Petrelli N, Herrera L, Rustum Y et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987;5:1559-65
13. Poon MA, O'Connell MJ, Moertel CG et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-18
14. Poon MA, O'Connell MJ, Wieand HS et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:1967-72
15. Buroker TR, O'Connell MJ, Wieand S et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12: 14-20
16. Scheithauer W, Kornek G, Depish D et al. Phase III study of 5-fluorouracil and leucovorin with or without cisplatin in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1992;11:195
17. Leichman CG, Fleming TR, Muggia FM et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995;13:1303-11
18. Valsecchi R, Labianca R, Cascinu S et al. High-dose versus low-dose 1-leucovorin as a modulator of 5-days 5-fuorouracil in advanced colorectal cancer: a GISCAD phase III study. Proc Am Soc Clin Oncol 1995;14:195
19. Borner MM, Bacchi M, Castiglione M et al. 5-fluorouracil with and without low-dose leucovorin for advanced colorectal carcinoma: a Swiss confirmatory phase III trial. Ann Oncol 1996;7 (Suppl 5):45
20. Cunnigham D, Zalcberg JR, Rath U et al. Final results of a randomised trial comparing tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996;7:961-5
21. Aranda E. Estudio fase III de 5-FU en infusion continua vs bolus. IV symposio internacional de tratamiento de tumores digestivos. Zaragoza (Espagne), 22-23 novembre 1996
22. de Gramont A, Bosset JF, Milan C et al. A randomized trial comparing monthly with low-dose leucovorin - fluorouracil bolus with bimonthly high-dose leucovorin - fluorouracil bolus plus continuous infusion for advanced colorectal cancer. A French Intergroup study. J Clin Oncol 1997;15:808-15
23. Seymour MT, Slevin M, Kerr DJ et al. Randomized trial assessing the addition of interferon α2a to fluorouracil and leucovorin in advanced colorectal cancer. J Clin Oncol 1996;14:2280-8
24. Ardalan B, Chua L, Tiang E et al. A phase II of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal cancer. J Clin Oncol 1991;9:625-30
25. Weh HJ, Hoffknecht M, Hölzer P et al. 5-FU/FA bolus therapy vs weekly high-dose 5-FU/FA 24-hour infusion in metastatic colorectal carcinoma. Preliminary results of an ongoing randomized phase III study. ECCO 8, Paris 29 Oct-2 Nov 1995. Eur J Cancer 1995;31A:S158
26. Beerblock K, Rinaldi Y, André T et al. Bimonthly high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in advanced colorectal cancer. Cancer 1997;79:1094-9